Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$3.96
-1.12%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
-11.0%
3 months
+58.4%
6 months
+40.4%
1 year
+45.0%
Year to date
+31.6%
52-week range
$2.00 – $4.65
Latest reported period: Jun 30, 2026
Market cap
$29.5M
P/E
-5.2
P/B
1.9
P/S
0.2
Revenue
$154.63M
Net income
-$5.72M
Diluted EPS
-0.76
Gross margin
69.40%
Net margin
-3.70%
Return on equity
-30.10%
Total debt
$24.04M
Cash
$5.19M
Free cash flow
-$1.45M
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $37.98M | -$5M | 67.10% | -13.20% | -$2.03M |
| Mar 31, 2026 | $37.26M | -$628K | 69.60% | -1.70% | -$922K |
| Dec 31, 2025 | $39.86M | $2.2M | 70.60% | 5.50% | -$685K |
| Sep 30, 2025 | $39.52M | -$2.29M | 70.30% | -5.80% | $2.19M |
| Jun 30, 2025 | $38.63M | -$335K | 67.90% | -0.90% | -$5.08M |
| Mar 31, 2025 | $41.56M | -$392K | 66.20% | -0.90% | -$921K |
| Dec 31, 2024 | $47.13M | -$2.43M | 68.60% | -5.20% | $3.42M |
| Sep 30, 2024 | $47.63M | $142K | 69.70% | 0.30% | -$4.86M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I have a cold again. Cure it, science. HHS opens peptide floodgates, despite...
Original sourceHealth Policy October 29, 20264:45 AM ET Heard on Morning Edition ...
Original sourceRFK Jr. has embraced peptides, though there’s little evidence of their safety or effectiveness Adobe Margaret is a Washington...
Original source